{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"}],"units":"Participants"}],"description":"Determine the incidence of chronic GVHD at 1 year after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria.\n\nPatients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.","groups":[{"description":"Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.","id":"OG000","title":"Unrelated UCBT for Blood Cancers"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Year 1","title":"Number of Participants With Chronic Graft-Versus-Host Disease","type":"SECONDARY","unitOfMeasure":"Participants"}